Atlas Trials

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Clinical trial NCT00866658 · COMPLETED

Trial details

NCT number
NCT00866658
Sponsor
Sanofi
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 2
Start date
2009-03-01
Primary completion
2010-06-01
Enrollment
311

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.